在6至11岁儿童的要求下ICS+FABA组合
Elsy M Navarrete-Rodríguez1, Blanca E Del-Rio-Navarro1, Désirée Larenas-Linnemann2
1Secretaría de Salud, Hospital Infantil de México Federico Gómez, Servicio de Alergia e Inmunología Clínica, Ciudad de Mexico 06760, Mexico.
Journal of clinical medicine
|December 9, 2023
概括
新的喘治疗策略,如吸入性皮质类固醇 (ICS) 以及快速起作用的β-激动剂 (FABA) 作为缓解剂,在6-11岁的儿童中显示出好处. 这种方法结合了抗炎和支气管扩展作用,改善了年轻患者的喘管理.
科学领域:
- 儿科肺病学 儿科肺病学
- 药理学 药理学是指药理学的学科.
- 喘治疗方法 喘治疗方法
背景情况:
- 最近的喘治疗进展包括"抗炎缓解剂"策略,结合吸入性皮质类固醇 (ICS) 和短效β-激动剂.
- 国际指南已经纳入了这些策略,主要是基于12岁以上患者的证据.
- 对于这些联合疗法在年幼儿童的疗效和安全性的证据有限.
研究的目的:
- 审查和分析关于在6至11岁儿童中使用ICS加快速起作用β-激动剂 (FABA) 联合治疗的现有信息.
- 评估这种治疗方法在患有喘的儿科患者群体中的潜在益处.
- 为了解决关于ICS + FABA在这个特定年龄组中的使用证据的稀缺性.
主要方法:
- 对已发表的临床试验进行系统审查,调查6-11岁儿童的ICS + FABA联合治疗.
- 分析了使用特定ICS/FABA组合的研究数据,例如贝克罗米他/阿尔布特罗尔和布德索尼德/福莫特罗尔.
- 从包含的试验中评估报告的疗效和安全结果.
主要成果:
- 三项已发表的试验为6至11岁儿童的ICS+FABA使用提供了重要的见解.
- 使用贝克洛梅他松+阿尔布特罗尔和布德森化物+福莫特罗尔的研究表明治疗效益.
- 现有的数据表明,这种组合治疗方法在目标儿科患者群体中具有积极的结果.
结论:
- ICS + FABA组合疗法在6至11岁儿童的喘管理方面显示出显著的潜在益处.
- 尽管试验数量有限,但现有证据支持在这个年龄组考虑这种"抗炎缓解剂"策略.
- 需要进一步的研究来扩大ICS + FABA在儿科喘患者的使用的证据基础.
更多相关视频
相关概念视频
Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...


